Clinical Trial Update: Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple Myeloma [Phase 2]

View source ↗

Summary

Phase 2 study evaluating oral ixazomib in combination with cyclophosphamide and dexamethasone for newly diagnosed or relapsed/refractory multiple myeloma; study…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• DEXAMETHASONE (Dexamethasone)
• ixazomib (ixazomib)

Snippet

Sponsor: Millennium Pharmaceuticals, Inc. | Conditions: Multiple Myeloma | Phase 2 | Status: COMPLETED | Results posted: 2019-07-17